Gross Margin % is calculated as gross profit divided by its revenue. Marizyme's Gross Profit for the
three
months ended in Mar. 2024 was $0.02 Mil. Marizyme's Revenue for the
three
months ended in Mar. 2024 was $0.03 Mil. Therefore, Marizyme's Gross Margin % for the quarter that ended in Mar. 2024 was 69.70%.
The historical rank and industry rank for Marizyme's Gross Margin % or its related term are showing as below:
MRZM'
s Gross Margin % Range Over the Past 10 Years
Min: 13.86 Med: 61.9 Max: 76.82
Current: 70.96
During the past 13 years, the highestGross Margin % of Marizyme was 76.82%. The lowest was 13.86%. And the median was 61.90%.
MRZM's Gross Margin % is ranked better than 62.27% of 750
companies
in the Biotechnology industry
Industry Median: 60.91
vs MRZM: 70.96
Marizyme had a gross margin of 69.70% for the quarter that ended in Mar. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Marizyme was 0.00% per year.
Marizyme Gross Margin % Historical Data
The historical data trend for Marizyme's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Marizyme's Gross Margin %
For the Biotechnology subindustry, Marizyme's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marizyme's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marizyme's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Marizyme's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Marizyme (OTCPK:MRZM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Marizyme had a gross margin of 69.70% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Marizyme Gross Margin % Related Terms
Thank you for viewing the detailed overview of Marizyme's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRZM has been successfully added to your 